Maze Therapeutics, Inc.
MAZEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. With a market capitalization of $1.72B, it sits in small-cap territory. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Market Cap
$1.72B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-9.73
EPS (TTM)
$-2.43
EPS (Fwd)
$-3.19
ROE
-37.4%
ROA
-21.8%
Cash
$411.1M
Total Debt
$60.4M
Free CF
-$63.6M
52W Change
0.0%
Annual Financials
Cash vs Debt
Where MAZE stands vs its 150-day and 200-day moving averages
As of the September 25, 2026 close, MAZE finished 13.41% below its 150-day moving average ($30.27) and 21.48% below its 200-day moving average ($33.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MAZE overbought or oversold?
At the September 25, 2026 close, MAZE's RSI(14) was 51.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $411.1M in cash comfortably exceeding the $60.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$63.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MAZE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.